Injection
From $169/month
Nasal spray
From $144/month
Oral tablets
From $169/month
Supply
One month stated on each product card

The lowest NAD+ headline belongs to a particular route

Shed's NAD+ page leads with a starting figure of $144, while its individual product cards identify injections from $169 per month, nasal spray from $144 per month and oral tablets from $169 per month. The route-specific cards are the useful comparison point. The lowest overall headline should not be copied onto the injection or tablet listing.

Each card describes a one-month supply. That gives a clearer commercial period than an unspecified vial price, but it does not establish the same ingredient quantity or clinical performance across all three products. We review the formats separately and have not obtained a prescription, received medication or tested the provider's service.

The care pathway involves review before fulfillment

Shed describes an online intake, a licensed clinician's assessment, pharmacy preparation when appropriate and support through its member portal. These steps explain the advertised process. They do not guarantee a prescription for every applicant or establish how quickly the complete process will occur for a particular person and location.

Ask which clinical and administrative services are included in the selected NAD+ price. The product cards should not be treated as a complete invoice for every possible assessment or added service. Also distinguish access to the portal from a measured medical-response time; this publication has not verified the speed or quality of individual support interactions.

Product identity matters beyond the format name

The reviewed page does not provide a complete vial, bottle or tablet specification for every prescription. Request the pharmacy, concentration, total quantity and supply instructions for the selected route. A shared one-month label does not establish equal absorbed amounts or justify replacing one preparation with another without clinical guidance.

The oral tablet also needs to be distinguished from an over-the-counter capsule or a supplement containing an NAD precursor. The page identifies compounded NAD+ options, so another manufacturer's capsule evidence cannot be treated as a trial of Shed's tablet. Route and ingredient identity should remain visible before comparing the numbers on the price cards.

Evidence and ongoing cost need separate confirmation

Shed identifies its compounded medications as not FDA-approved. Its explanations of cellular energy and aging describe NAD+ biology and marketed goals, rather than proof that every finished preparation delivers a predictable improvement. We did not verify a comparative trial establishing that its three routes are clinically equivalent or that the more expensive routes produce better outcomes.

Before enrolling, obtain the full charge, renewal schedule, cancellation conditions and pharmacy-specific storage information. Keep any weight-loss promotions or guarantees elsewhere on the site separate from the NAD+ purchase unless the provider expressly applies them to it. Shed contributes three documented route-specific starting prices to the register; the final decision requires the actual prescription and complete care agreement, not the lowest number in the shared heading.

Useful distinctions

  • Three route-specific prices on one page
  • Each card states a supply period
  • Online assessment and follow-up pathway described

Limitations to weigh

  • Exact dispensed quantities need confirmation
  • Headline $144 is not the injection price
  • Compounded products and clinical equivalence remain distinct issues

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Shed: injection, nasal and oral NAD+ offers Provider
  2. FDA: Compounding questions and answers Regulator
  3. PubChem: Nicotinamide adenine dinucleotide Chemical reference